News

Oyster Point Pharma Announces TYRVAYA® To Be Covered By the Largest Medicare Pharmacy Benefit Manager

PRINCETON, N.J., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), (“Oyster Point Pharma”, or “the Company”),…

2 years ago

Enlivex Receives Israeli Ministry of Health Approval for the Initiation of a Phase I/II Trial Evaluating Allocetra™ Alone and in Combination with a PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors

Trial builds on encouraging preclinical studies conducted in collaboration with Yale Cancer Center that showed a substantial, statistically significant survival…

2 years ago

Magenta Therapeutics Appoints Michael Vasconcelles, M.D. to the Board of Directors

CAMBRIDGE, Mass., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed…

2 years ago

Coloplast Finance B.V. – 9M Interim Financial Report 2021/2022

Coloplast B.V. - Announcement no. 02/2022 - Interim Financial Report, 9M 2021/2022   9M 2021/22 Interim financial results, 9M 2021/22…

2 years ago

CloudMD Provides Business Update on Customer Momentum

VANCOUVER, British Columbia, Aug. 17, 2022 (GLOBE NEWSWIRE) -- CloudMD Software & Services Inc. (TSXV: DOC, OTCQX: DOCRF, Frankfurt: 6PH)…

2 years ago

Kraig Biocraft Laboratories Expands Operational Footprint in Vietnam

ANN ARBOR, Mich., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), the…

2 years ago

Tilray Medical Bolsters Market Leading Position in Europe With Market Authorization in Poland

Polish Ministry of Health Approves Tilray Branded Medical Cannabis for Pharmaceutical Distribution in Addition to Wholesale ApprovalLEAMINGTON, Ontario and CANTANHEDE,…

2 years ago

Kamada Reports Second Quarter and First Half 2022 Financial Results; Significant Growth Driven by Multiple Catalysts Expected in Second Half of 2022; Reiterates 2022 Revenue and Profitability Guidance

Second Quarter 2022 Revenues were $23.6 Million; First Half 2022 Revenues of $51.7 Million Increased 5% Year-Over-YearFirst Half 2022 Adjusted…

2 years ago

Health Canada Grants MDMA Production and Distribution Amendment to Optimi Health

CEO says licensing amendment positions Optimi to be a “global leader in the safe supply of EU-GMP Psilocybin, MDMA, and…

2 years ago